Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern (VoC) are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. The yet-to-be peer-reviewed study, posted on the preprint server MedRxiv Read More